-
Allergan to acquire Tobira Therapeutics
DUBLIN and SAN FRANCISCO — Allergan has announced an acquisition aimed at making it a leader in the development of treatment for nonalcoholic steatohepatitis (NASH), a disease state seeing increased interest from drug makers. The company will be acquiring clinical-stage biotech company Tobira Therapeutics in a deal with a total potential value of $1.69 billion.